Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie outdoes rumored J&J bid with $21bn Pharmacyclics buy

This article was originally published in Scrip

Executive Summary

AbbVie swooped in to buy Pharmacyclics for $21bn on 4 March after several days of speculation that the Sunnyvale, California-based biopharmaceutical firm would be acquired by its Imbruvica (ibrutinib) development partner Johnson & Johnson for as much as $19bn.

Advertisement

Related Content

After Imbruvica Passes Chemo-Free Tests, Shorter Duration Regimens Could Be Next Value-Adds
AbbVie, J&J's Imbruvica Has Rare, But Not Surprising Failure In DLBCL
Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash
AbbVie Partners With Argenx In Cancer Deal Spree

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC027999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel